At a glance
- Originator Bristol-Myers Squibb
- Class Anxiolytics
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 02 Sep 1998 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 18 Dec 1995 Preclinical development for Anxiety disorders in USA (Unknown route)